Welcome to our dedicated page for Tiziana Life Sciences Com SEC filings (Ticker: TLSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tiziana Life Sciences Ltd. filings document foreign-private-issuer material-event disclosures for a clinical-stage biotechnology company developing intranasal foralumab, a fully human anti-CD3 monoclonal antibody. The company’s Form 6-K reports furnish press-release exhibits on clinical and preclinical data, biomarker findings, peer-reviewed study publications, conference presentations, and program activity in neuroinflammatory and neurodegenerative diseases.
The filing record also includes capital-structure disclosures tied to registered direct offerings of ordinary shares and warrants, together with governance and security-structure information relevant to the company’s Nasdaq-listed ordinary shares and foreign issuer reporting framework.